Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hanmi Pharma Will Build a New $200 Million Plant in China

publication date: Apr 6, 2016
Hanmi Pharma of South Korea will build a second China manufacturing facility, which will be located in the northeast city of Yantai. The company recently paid $10 million for 200,000 square meters of land in the Yantai Economic and Technological Development Zone, and it intends to invest $200 million over the next ten years to increase its chemical and biological drug production facilities there. Eventually, the company will also add an R&D operation in Yantai. in 2015, Hanmi signed deals for up to $6.5 billion for global rights to its development-stage drugs. More details....

Stock Symbol: (KS: 128940)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital